| |
| The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors. |
| |
|
|
| Abstract Details |
 |
|
| |
| |
| |
|
|
| |
Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon-alpha-2b-ribavirin combination therapy |
|
|
|
|
| |
Fran�ois C, Descamps V, Brochot E, Bernard I, Canva V, Mathurin P, Castelain S, Duverlie G. J Med Virol. 2010 Oct;82(10):1640-6. |
|
| |
|
|
| |
Abstract
In chronic hepatitis C virus (HCV) infections, the current standard of care (combination therapy with pegylated alpha interferon (PEG-IFN?) and ribavirin) is only effective in around 50% of cases. The aim of the present study was to analyze the relationship between the HCV load and the PEG-IFN concentration during the first week of treatment. Fifteen treatment-naive patients with chronic hepatitis C infection (genotypes 1, 2, 3, and 4) underwent PEG-IFN?-2b/ribavirin combination therapy. Blood samples were collected before the first injection (T(0)) and then at different time points until the next injection a week later. The PEG-IFN concentration and the HCV load were assayed. The serum interferon concentration peaked 2 days after the first injection (mean value for the study population; T(max)?=?40.9?hr; C(max)?=?490?pg/ml) and a trough in viral load was seen at day 3. The PEG-IFN?-2b concentration decreased from day 2 to day 7, enabling a viral rebound in all patients. The change in viral load between day 0 and day 3 differed significantly according to whether the patients were responders at week 12 (?log?d(0)/d(3)?=?2.729?�?1.419?log(10)?IU/ml) or not (?log?d(0)/d(3)?=?1.102?�?0.472?log(10)?IU/ml). Our results emphasize the potential clinical importance of achieving viral decay immediately after initiation of interferon-ribavirin combination therapy.
|
|
|
|
| |
| |
|